{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T18:36:10Z","timestamp":1791916570829,"version":"4.3.4"},"reference-count":233,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,6,4]],"date-time":"2018-06-04T00:00:00Z","timestamp":1528070400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["5R01 CA185372"],"award-info":[{"award-number":["5R01 CA185372"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2018.00163","type":"journal-article","created":{"date-parts":[[2018,6,4]],"date-time":"2018-06-04T04:12:07Z","timestamp":1528085527000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":351,"title":["Past, Present, and Future of Rituximab\u2014The World\u2019s First Oncology Monoclonal Antibody Therapy"],"prefix":"10.3389","volume":"8","author":[{"given":"Timothy M.","family":"Pierpont","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candice B.","family":"Limper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristy L.","family":"Richards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,6,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/256495a0","article-title":"Continuous cultures of fused cells secreting antibody of predefined specificity","volume":"256","author":"K\u00f6hler","year":"1975","journal-title":"Nature"},{"key":"B2","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/nrd1386","article-title":"Monoclonal antibodies market","volume":"3","author":"Reichert","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"B3","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/nri2763","article-title":"Therapeutic antibodies: past, present and future","volume":"10","author":"Leavy","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"B4","first-page":"3147","article-title":"Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen","volume":"40","author":"Nadler","year":"1980","journal-title":"Cancer Res"},{"key":"B5","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/312643a0","article-title":"Production of functional chimaeric mouse\/human antibody","volume":"312","author":"Boulianne","year":"1984","journal-title":"Nature"},{"key":"B6","doi-asserted-by":"publisher","first-page":"6851","DOI":"10.1073\/pnas.81.21.6851","article-title":"Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains","volume":"81","author":"Morrison","year":"1984","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B7","doi-asserted-by":"publisher","first-page":"3266","DOI":"10.1200\/JCO.1997.15.10.3266","article-title":"IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin\u2019s lymphoma","volume":"15","author":"Maloney","year":"1997","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1182\/blood.V84.8.2457.2457","article-title":"Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma","volume":"84","author":"Maloney","year":"1994","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"key":"B10","article-title":"The top 15 best-selling drugs of 2016","volume-title":"The Lists","author":"Philippidis","year":"2017"},{"key":"B11","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/nri213333","article-title":"B-cell anergy: from transgenic models to naturally occurring anergic B cells?","volume":"7","author":"Cambier","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e104","DOI":"10.1212\/NXI.0000000000000104","article-title":"B lymphocytes in neuromyelitis optica","volume":"2","author":"Bennett","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B13","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.blre.2017.05.002","article-title":"Dancing partners at the ball: rational selection of next generation anti-CD20 antibodies for combination therapy of chronic lymphocytic leukemia in the novel agents era","volume":"31","author":"Butler","year":"2017","journal-title":"Blood Rev"},{"key":"B14","doi-asserted-by":"publisher","first-page":"42427","DOI":"10.1074\/jbc.M308802200","article-title":"Store-operated cation entry mediated by CD20 in membrane rafts","volume":"278","author":"Li","year":"2003","journal-title":"J Biol Chem"},{"key":"B15","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/intimm\/dxh009","article-title":"Mouse CD20 expression and function","volume":"16","author":"Uchida","year":"2004","journal-title":"Int Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40364-017-0088-5","article-title":"Diagnosis and treatment of CD20 negative B cell lymphomas","volume":"16","author":"Katchi","year":"2017","journal-title":"Biomark Res"},{"key":"B17","doi-asserted-by":"crossref","first-page":"5081","DOI":"10.1182\/blood.V126.23.5081.5081","article-title":"Rituximab maintenance therapy is an effective therapy in over-sixties with mantle cell lymphoma","volume":"126","author":"Inoue","year":"2015","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1080\/17474086.2017.1305264","article-title":"Diffuse large B-cell lymphoma in the elderly: standard treatment and new perspectives","volume":"10","author":"Chiappella","year":"2017","journal-title":"Expert Rev Hematol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","first-page":"4587","DOI":"10.1200\/JCO.2007.15.9277","article-title":"Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma","volume":"26","author":"Fu","year":"2008","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1200\/JCO.2001.19.2.389","article-title":"Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin\u2019s lymphoma","volume":"19","author":"Vose","year":"2001","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1200\/JCO.2005.05.1003","article-title":"Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma","volume":"24","author":"Habermann","year":"2006","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","article-title":"CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group","volume":"7","author":"Pfreundschuh","year":"2006","journal-title":"Lancet Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/S1470-2045(11)70235-2","article-title":"CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group","volume":"12","author":"Pfreundschuh","year":"2011","journal-title":"Lancet Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.critrevonc.2017.01.009","article-title":"Primary mediastinal large B-cell lymphoma","volume":"113","author":"Martelli","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ctrv.2016.11.015","article-title":"Rituximab: 13 open questions after 20 years of clinical use","volume":"53","author":"Pavanello","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"B28","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/bjh.14860","article-title":"Optimization of rituximab for the treatment of DLBCL: increasing the dose for elderly male patients","volume":"179","author":"Pfreundschuh","year":"2017","journal-title":"Br J Haematol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e0174648","DOI":"10.1371\/journal.pone.0174648","article-title":"Rituximab maintenance therapy for patients with diffuse large B-cell lymphoma: a meta-analysis","volume":"12","author":"Zhou","year":"2017","journal-title":"PLoS One"},{"key":"B30","doi-asserted-by":"publisher","first-page":"3870","DOI":"10.1182\/blood-2014-03-563627","article-title":"Improved outcome of adult Burkitt lymphoma\/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial","volume":"124","author":"Hoelzer","year":"2014","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00277-015-2501-1","article-title":"Effect of rituximab on adult Burkitt\u2019s lymphoma: a systematic review and meta-analysis","volume":"95","author":"Nie","year":"2016","journal-title":"Ann Hematol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1016\/S0140-6736(15)01317-3","article-title":"Rituximab and dose-dense chemotherapy for adults with Burkitt\u2019s lymphoma: a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Ribrag","year":"2016","journal-title":"Lancet"},{"key":"B33","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1111\/bjh.13764","article-title":"Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20+ rituximab-sensitive\/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia (pre-B-ALL): potential targeted therapy in patients with poor risk CD20+BL and pre-B-ALL","volume":"171","author":"Awasthi","year":"2015","journal-title":"Br J Haematol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10428194.2017.1403602","article-title":"Treatment for patients with relapsed\/refractory mantle cell lymphoma: European-based recommendations","author":"Dreyling","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1016\/j.clml.2017.10.006","article-title":"VcR-CVAD induction chemotherapy followed by maintenance rituximab produces durable remissions in mantle cell lymphoma: a Wisconsin Oncology Network Study","volume":"18","author":"Chang","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B36","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1093\/jnci\/djk152","article-title":"Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis","volume":"99","author":"Schulz","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1056\/NEJMoa1701769","article-title":"Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma","volume":"377","author":"Le Gouill","year":"2017","journal-title":"N Engl J Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1016\/j.bbmt.2006.07.007","article-title":"Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma","volume":"12","author":"Ladetto","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"B39","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.bbmt.2016.12.634","article-title":"Molecular monitoring after autologous stem cell transplantation and preemptive rituximab treatment of molecular relapse; results from the nordic mantle cell lymphoma studies (MCL2 and MCL3) with median follow-up of 8.5 years","volume":"23","author":"Kolstad","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"B40","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s11864-017-0459-z","article-title":"Maintenance therapies in indolent lymphomas: should recent data change the standard of care?","volume":"18","author":"Tees","year":"2017","journal-title":"Curr Treat Options Oncol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00277-017-3154-z","article-title":"Current prognostic and predictive factors in follicular lymphoma","volume":"97","author":"Sorigue","year":"2017","journal-title":"Ann Hematol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"131","DOI":"10.2147\/CMAR.S120589","article-title":"Rituximab in the treatment of follicular lymphoma: the future of biosimilars in the evolving therapeutic landscape","volume":"9","author":"Subramanian","year":"2017","journal-title":"Cancer Manag Res"},{"key":"B43","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","article-title":"IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin9s lymphoma","volume":"90","author":"Maloney","year":"1997","journal-title":"Blood"},{"key":"B44","first-page":"88","article-title":"CHOP plus rituximab chemoimmunotherapy of indolent B-cell lymphoma","volume":"26","author":"Czuczman","year":"1999","journal-title":"Semin Oncol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.1093\/annonc\/mdx496","article-title":"A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin\u2019s lymphoma (NHL): CALGB 50803 (Alliance)","volume":"28","author":"Martin","year":"2017","journal-title":"Ann Oncol"},{"key":"B46","volume-title":"US Food and Drug Administration Approves REVLIMID","author":"Levin","year":""},{"key":"B47","doi-asserted-by":"publisher","first-page":"e2017009","DOI":"10.4084\/MJHID.2017.009","article-title":"Follicular lymphoma: the management of elderly patient","volume":"9","author":"Castellino","year":"2017","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"B48","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/S1470-2045(14)70027-0","article-title":"Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial","volume":"15","author":"Ardeshna","year":"2014","journal-title":"Lancet Oncol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet"},{"key":"B50","article-title":"Updated 6 year follow-up of the PRIMA study confirms the benefit of 2-year rituximab maintenance in follicular lymphoma patients responding to frontline immunochemotherapy","volume":"122","author":"Seymour","year":"2013","journal-title":"Blood"},{"key":"B51","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nri.2015.9","article-title":"Natural killer cell memory in infection, inflammation and cancer","volume":"16","author":"Cerwenka","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.ejca.2017.01.021","article-title":"Rituximab maintenance improves overall survival of patients with follicular lymphoma \u2013 individual patient data meta-analysis","volume":"76","author":"Vidal","year":"2017","journal-title":"Eur J Cancer"},{"key":"B53","doi-asserted-by":"publisher","first-page":"895105","DOI":"10.1155\/2015\/895105","article-title":"Rituximab as single agent in primary MALT lymphoma of the ocular adnexa","volume":"2015","author":"Annibali","year":"2015","journal-title":"Biomed Res Int"},{"key":"B54","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1159\/000074641","article-title":"Rituximab for treatment of advanced extranodal marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue lymphoma","volume":"65","author":"Raderer","year":"2003","journal-title":"Oncology"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1182\/blood-2017-03-771915","article-title":"A MALT lymphoma prognostic index","volume":"130","author":"Thieblemont","year":"2017","journal-title":"Blood"},{"key":"B56","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.beha.2016.07.004","article-title":"Treatment of splenic marginal zone lymphoma","volume":"30","author":"Kalpadakis","year":"2017","journal-title":"Best Pract Res Clin Haematol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1182\/blood-2015-12-624296","article-title":"Optimizing therapy for nodal marginal zone lymphoma","volume":"127","author":"Thieblemont","year":"2016","journal-title":"Blood"},{"key":"B58","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1080\/17474086.2017.1339596","article-title":"Current options to manage Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"10","author":"Benevolo","year":"2017","journal-title":"Expert Rev Hematol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1600-0609.2008.01171.x","article-title":"Update on therapeutic options in Waldenstr\u00f6m macroglobulinemia","volume":"82","author":"Leleu","year":"2009","journal-title":"Eur J Haematol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1200\/JCO.2002.09.039","article-title":"Treatment of Waldenstr\u00f6m\u2019s macroglobulinemia with rituximab","volume":"20","author":"Dimopoulos","year":"2002","journal-title":"J Clin Oncol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/bjh.14826","article-title":"Dexamethasone, rituximab and cyclophosphamide for relapsed and\/or refractory and treatment-na\u00efve patients with Waldenstrom macroglobulinemia","volume":"179","author":"Paludo","year":"2017","journal-title":"Br J Haematol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1182\/blood-2015-01-553974","article-title":"How I treat Waldenstr\u00f6m macroglobulinemia","volume":"126","author":"Treon","year":"2015","journal-title":"Blood"},{"key":"B63","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/j.1365-2141.2011.08750.x","article-title":"Maintenance rituximab is associated with improved clinical outcome in rituximab na\u00efve patients with Waldenstrom macroglobulinaemia who respond to a rituximab-containing regimen","volume":"154","author":"Treon","year":"2011","journal-title":"Br J Haematol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1182\/blood-2016-01-689422","article-title":"Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia","volume":"129","author":"Grever","year":"2017","journal-title":"Blood"},{"key":"B65","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.beha.2015.10.018","article-title":"Historical overview of hairy cell leukemia","volume":"28","author":"Andritsos","year":"2015","journal-title":"Best Pract Res Clin Haematol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1111\/bjh.14129","article-title":"Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial","volume":"174","author":"Chihara","year":"2016","journal-title":"Br J Haematol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.biopha.2017.10.105","article-title":"Advances in chronic lymphocytic leukemia pharmacotherapy","volume":"97","author":"Gomes","year":"2018","journal-title":"Biomed Pharmacother"},{"key":"B68","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1080\/10428190210178","article-title":"Level of CD 20-expression and efficacy of rituximab treatment in patients with resistant or relapsing B-cell prolymphocytic leukemia and B-cell chronic lymphocytic leukemia","volume":"43","author":"Perz","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"B69","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1053\/j.seminhematol.2010.01.005","article-title":"Rituximab in chronic lymphocytic leukemia","volume":"47","author":"Jaglowski","year":"2010","journal-title":"Semin Hematol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1186\/s13063-017-2138-6","article-title":"Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial","volume":"18","author":"Collett","year":"2017","journal-title":"Trials"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10428194.2017.1387904","article-title":"Improved survival outcomes with the addition of rituximab to initial therapy for chronic lymphocytic leukemia: a comparative effectiveness analysis in the province of British Columbia, Canada","author":"Lee","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"B72","doi-asserted-by":"publisher","first-page":"2891","DOI":"10.2147\/DDDT.S139248","article-title":"Current perspective on rituximab in rheumatic diseases","volume":"11","author":"Schioppo","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"B73","doi-asserted-by":"publisher","first-page":"928","DOI":"10.2340\/00015555-2116","article-title":"Efficacy of rituximab for pemphigus: a systematic review and meta-analysis of different regimens","volume":"95","author":"Wang","year":"2015","journal-title":"Acta Derm Venereol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/archdermatol.2011.54","article-title":"Rituximab for patients with refractory mucous membrane pemphigoid","volume":"147","author":"Le Roux-Villet","year":"2011","journal-title":"Arch Dermatol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s00415-014-7532-3","article-title":"Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis","volume":"262","author":"Iorio","year":"2015","journal-title":"J Neurol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1177\/1352458515602337","article-title":"Efficacy of rituximab in refractory neuromyelitis optica","volume":"22","author":"Collongues","year":"2016","journal-title":"Mult Scler"},{"key":"B77","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum"},{"key":"B78","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1002\/art.34359","article-title":"Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study","volume":"64","author":"Rovin","year":"2012","journal-title":"Arthritis Rheum"},{"key":"B79","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N Engl J Med"},{"key":"B80","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.pharmthera.2010.01.001","article-title":"Targeting B cells in immune-mediated inflammatory disease: a comprehensive review of mechanisms of action and identification of biomarkers","volume":"125","author":"D\u00f6rner","year":"2010","journal-title":"Pharmacol Ther"},{"key":"B81","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2217\/ijr.12.7","article-title":"Living life without B cells: is repeated B-cell depletion a safe and effective long-term treatment plan for rheumatoid arthritis?","volume":"7","author":"Chen","year":"2012","journal-title":"Int J Clin Rheumatol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1182\/asheducation-2016.1.366","article-title":"Diffuse large B-cell lymphoma: R-CHOP failure\u2014what to do?","volume":"2016","author":"Coiffier","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jnci\/djw257","article-title":"Beyond RCHOP: a blueprint for diffuse large B cell lymphoma research","volume":"108","author":"Nowakowski","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"B84","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1007\/s12325-017-0610-z","article-title":"Subcutaneous rituximab for the treatment of B-cell hematologic malignancies: a review of the scientific rationale and clinical development","volume":"34","author":"Davies","year":"2017","journal-title":"Adv Ther"},{"key":"B85","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/S1470-2045(14)70005-1","article-title":"Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study","volume":"15","author":"Davies","year":"2014","journal-title":"Lancet Oncol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00277-017-3147-y","article-title":"SMABcare study: subcutaneous monoclonal antibody in cancer care: cost-consequence analysis of subcutaneous rituximab in patients with follicular lymphoma","volume":"97","author":"Fargier","year":"2017","journal-title":"Ann Hematol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10238-006-0087-6","article-title":"Radioimmunotherapy of B-cell lymphoma with radiolabelled anti-CD20 monoclonal antibodies","volume":"6","author":"Dillman","year":"2006","journal-title":"Clin Exp Med"},{"key":"B88","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1158\/0008-5472.CAN-16-2523","article-title":"Whither radioimmunotherapy: to be or not to be?","volume":"77","author":"Green","year":"2017","journal-title":"Cancer Res"},{"key":"B89","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1111\/cbdd.13010","article-title":"Novel reduction-sensitive micellar nanoparticles assembled from rituximab\u2013doxorubicin conjugates as smart and intuitive drug delivery systems for the treatment of non-Hodgkin\u2019s lymphoma","volume":"90","author":"Yin","year":"2017","journal-title":"Chem Biol Drug Des"},{"key":"B90","doi-asserted-by":"publisher","first-page":"347","DOI":"10.4172\/1948-5956.1000373","article-title":"Development of novel anti-Cd20 monoclonal antibodies and modulation in Cd20 levels on cell surface: looking to improve immunotherapy response","volume":"7","author":"Singh","year":"2015","journal-title":"J Cancer Sci Ther"},{"key":"B91","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1517\/14712598.2015.1055241","article-title":"Ofatumumab in the treatment of non-Hodgkin\u2019s lymphomas","volume":"15","author":"Karlin","year":"2015","journal-title":"Expert Opin Biol Ther"},{"key":"B92","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/1756-8722-5-64","article-title":"Novel CD20 monoclonal antibodies for lymphoma therapy","volume":"5","author":"Cang","year":"2012","journal-title":"J Hematol Oncol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1056\/NEJMc1714146","article-title":"Ofatumumab for TTP in a patient with anaphylaxis associated with rituximab","volume":"378","author":"Crowley","year":"2018","journal-title":"N Engl J Med"},{"key":"B94","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1002\/ajh.24826","article-title":"Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment","volume":"92","author":"Hallek","year":"2017","journal-title":"Am J Hematol"},{"key":"B95","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1200\/JCO.2009.25.3187","article-title":"Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia","volume":"28","author":"Wierda","year":"2010","journal-title":"J Clin Oncol"},{"key":"B96","doi-asserted-by":"publisher","first-page":"5126","DOI":"10.1182\/blood-2011-04-348656","article-title":"Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study","volume":"118","author":"Wierda","year":"2011","journal-title":"Blood"},{"key":"B97","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1200\/JCO.2001.19.8.2165","article-title":"Rituximab dose-escalation trial in chronic lymphocytic leukemia","volume":"19","author":"O\u2019Brien","year":"2001","journal-title":"J Clin Oncol"},{"key":"B98","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s00277-014-2269-8","article-title":"Results of a phase II study of bendamustine and ofatumumab in untreated indolent B cell non-Hodgkin\u2019s lymphoma","volume":"94","author":"Czuczman","year":"2015","journal-title":"Ann Hematol"},{"key":"B99","first-page":"485","article-title":"Randomized phase 2 trial of ofatumumab and bendamustine versus ofatumumab, bendamustine, and bortezomib induction and maintenance therapy in patients (pts) with previously untreated high risk follicular lymphoma (FL): results from CALGB 50904 (alliance)","volume":"130","author":"Blum","year":"2017","journal-title":"Blood"},{"key":"B100","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/19420862.2016.1255520","article-title":"Rethinking the INN system for therapeutic antibodies","volume":"9","author":"Pottier","year":"2016","journal-title":"MAbs"},{"key":"B101","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1182\/blood-2014-07-586610","article-title":"Obinutuzumab (GA101) in relapsed\/refractory chronic lymphocytic leukemia: final data from the phase 1\/2 GAUGUIN study","volume":"124","author":"Cartron","year":"2014","journal-title":"Blood"},{"key":"B102","doi-asserted-by":"publisher","first-page":"3902","DOI":"10.1158\/1078-0432.CCR-14-0516","article-title":"U.S. Food and Drug Administration Approval: obinutuzumab in combination with chlorambucil for the treatment of previously untreated chronic lymphocytic leukemia","volume":"20","author":"Lee","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B103","doi-asserted-by":"publisher","first-page":"3529","DOI":"10.1200\/JCO.2017.73.3402","article-title":"Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma","volume":"35","author":"Vitolo","year":"2017","journal-title":"J Clin Oncol"},{"key":"B104","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the first-line treatment of follicular lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"N Engl J Med"},{"key":"B105","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s11523-017-0485-6","article-title":"Obinutuzumab: a review in rituximab-refractory or -relapsed follicular lymphoma","volume":"12","author":"Dhillon","year":"2017","journal-title":"Target Oncol"},{"key":"B106","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2147\/DDDT.S104869","article-title":"Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapy","volume":"11","author":"Al-Sawaf","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"B107","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1111\/bjh.14447","article-title":"Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and\/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial","volume":"176","author":"Sharman","year":"2017","journal-title":"Br J Haematol"},{"key":"B108","doi-asserted-by":"publisher","first-page":"370","DOI":"10.3389\/fimmu.2017.00370","article-title":"Modeling natural killer cell targeted immunotherapies","volume":"8","author":"Lopez-Lastra","year":"2017","journal-title":"Front Immunol"},{"key":"B109","doi-asserted-by":"publisher","first-page":"E9626","DOI":"10.1073\/pnas.1705301114","article-title":"Humanized mouse model supports development, function, and tissue residency of human natural killer cells","volume":"114","author":"Herndler-Brandstetter","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B110","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1158\/1541-7786.MCR-11-0154","article-title":"Direct effect of rituximab in B-cell-derived lymphoid neoplasias: mechanism, regulation, and perspectives","volume":"9","author":"Bezombes","year":"2011","journal-title":"Mol Cancer Res"},{"key":"B111","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/j.1365-2567.2005.02213.x","article-title":"Cholesterol depletion inhibits src family kinase-dependent calcium mobilization and apoptosis induced by rituximab crosslinking","volume":"116","author":"Unruh","year":"2005","journal-title":"Immunology"},{"key":"B112","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.critrevonc.2015.09.001","article-title":"A molecular perspective on rituximab: a monoclonal antibody for B cell non Hodgkin lymphoma and other affections","volume":"97","author":"Seyfizadeh","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"B113","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1172\/JCI37884","article-title":"Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells","volume":"119","author":"Ivanov","year":"2009","journal-title":"J Clin Invest"},{"key":"B114","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1053\/j.seminhematol.2010.01.011","article-title":"Rituximab: mechanism of action","volume":"47","author":"Weiner","year":"2010","journal-title":"Semin Hematol"},{"key":"B115","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.abb.2012.02.011","article-title":"Mechanism of action of therapeutic monoclonal antibodies: promises and pitfalls of in vitro and in vivo assays","volume":"526","author":"Golay","year":"2012","journal-title":"Arch Biochem Biophys"},{"key":"B116","doi-asserted-by":"publisher","first-page":"5567","DOI":"10.1182\/blood-2009-10-249466","article-title":"Complement: help or hindrance?","volume":"114","author":"Beers","year":"2009","journal-title":"Blood"},{"key":"B117","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1093\/intimm\/dxs048","article-title":"High reproducible ADCC analysis revealed a competitive relation between ADCC and CDC and differences between Fc\u03b3Rllla polymorphism","volume":"24","author":"Mishima","year":"2012","journal-title":"Int Immunol"},{"key":"B118","first-page":"676","article-title":"Mechanisms of action of CD20 antibodies","volume":"2","author":"Boross","year":"2012","journal-title":"Am J Cancer Res"},{"key":"B119","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/leu.2014.146","article-title":"Complement deficiencies limit CD20 monoclonal antibody treatment efficacy in CLL","volume":"29","author":"Middleton","year":"2015","journal-title":"Leukemia"},{"key":"B120","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1182\/blood-2010-07-298356","article-title":"The future of anti-CD20 monoclonal antibodies: are we making progress?","volume":"117","author":"Alduaij","year":"2011","journal-title":"Blood"},{"key":"B121","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1084\/jem.20040119","article-title":"The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy","volume":"199","author":"Uchida","year":"2004","journal-title":"J Exp Med"},{"key":"B122","doi-asserted-by":"publisher","first-page":"109","DOI":"10.5114\/ceji.2014.42135","article-title":"Perforin: an important player in immune response","volume":"39","author":"Osi\u0144ska","year":"2014","journal-title":"Cent Eur J Immunol"},{"key":"B123","volume-title":"Surgical Oncology","author":"Bartlett","year":"2011"},{"key":"B124","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/74704","article-title":"Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets","volume":"6","author":"Clynes","year":"2000","journal-title":"Nat Med"},{"key":"B125","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1128\/CDLI.8.6.1131-1135.2001","article-title":"Calcein-acetyoxymethyl cytotoxicity assay: standardization of a method allowing additional analyses on recovered effector cells and supernatants","volume":"8","author":"Neri","year":"2001","journal-title":"Clin Diagn Lab Immunol"},{"key":"B126","doi-asserted-by":"publisher","first-page":"sre19772","DOI":"10.1038\/srep19772","article-title":"A novel method for evaluating antibody-dependent cell-mediated cytotoxicity by flowcytometry using cryopreserved human peripheral blood mononuclear cells","volume":"6","author":"Yamashita","year":"2016","journal-title":"Sci Rep"},{"key":"B127","doi-asserted-by":"publisher","first-page":"3908289","DOI":"10.1155\/2017\/3908289","article-title":"A novel system for the quantification of the ADCC activity of therapeutic antibodies","volume":"2017","author":"Lallemand","year":"2017","journal-title":"J Immunol Res"},{"key":"B128","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1182\/blood-2016-08-735605","article-title":"Human neutrophils mediate trogocytosis rather than phagocytosis of CLL B cells opsonized with anti-CD20 antibodies","volume":"129","author":"Valgardsdottir","year":"2017","journal-title":"Blood"},{"key":"B129","doi-asserted-by":"publisher","first-page":"3438","DOI":"10.4049\/jimmunol.1101189","article-title":"Loss of CD20 and bound CD20 antibody from opsonized B cells occurs more rapidly because of trogocytosis mediated by Fc receptor-expressing effector cells than direct internalization by the B cells","volume":"187","author":"Beum","year":"2011","journal-title":"J Immunol"},{"key":"B130","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1158\/1535-7163.MCT-15-0335","article-title":"Macrophage-mediated trogocytosis leads to death of antibody-opsonized tumor cells","volume":"15","author":"Velmurugan","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"B131","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1158\/1078-0432.CCR-07-1254","article-title":"Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels","volume":"14","author":"Czuczman","year":"2008","journal-title":"Clin Cancer Res"},{"key":"B132","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7717\/peerj.31","article-title":"Analysis of innate and acquired resistance to anti-CD20 antibodies in malignant and nonmalignant B cells","volume":"1","author":"Small","year":"2013","journal-title":"PeerJ"},{"key":"B133","doi-asserted-by":"crossref","first-page":"4819","DOI":"10.1182\/blood.V106.11.4819.4819","article-title":"Loss of expression of the pro-apoptotic Bcl-2 family proteins bak and bax in rituximab- and chemotherapy-resistant non-Hodgkin\u2019s lymphoma cells","volume":"106","author":"Olejniczak","year":"2005","journal-title":"Blood"},{"key":"B134","first-page":"1183","article-title":"Rituximab (anti-CD20) selectively modifies Bcl-xL and apoptosis protease activating factor-1 (Apaf-1) expression and sensitizes human non-Hodgkin\u2019s lymphoma B cell lines to paclitaxel-induced apoptosis","volume":"2","author":"Jazirehi","year":"2003","journal-title":"Mol Cancer Ther"},{"key":"B135","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.neo.2017.06.001","article-title":"The antitumor activity of IMGN529, a CD37-targeting antibody-drug conjugate, is potentiated by rituximab in non-Hodgkin lymphoma models","volume":"19","author":"Hicks","year":"2017","journal-title":"Neoplasia"},{"key":"B136","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.ijrobp.2005.06.032","article-title":"Combining radiotherapy and immunotherapy: a revived partnership","volume":"63","author":"Demaria","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B137","doi-asserted-by":"publisher","first-page":"7102","DOI":"10.1158\/0008-5472.CAN-10-1316","article-title":"Chemotherapy-induced genotoxic stress promotes sensitivity to natural killer cell cytotoxicity by enabling missing-self recognition","volume":"70","author":"Fine","year":"2010","journal-title":"Cancer Res"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1038\/tpj.2017.37","article-title":"The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab","author":"Magnes","year":"2017","journal-title":"Pharmacogenomics J"},{"key":"B139","doi-asserted-by":"publisher","first-page":"4717","DOI":"10.1200\/jco.2004.22.14_suppl.6503","article-title":"Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype","volume":"22","author":"Weng","year":"2004","journal-title":"J Clin Oncol"},{"key":"B140","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1007\/s00277-016-2731-x","article-title":"Impact of Fc gamma-receptor polymorphisms on the response to rituximab treatment in children and adolescents with mature B cell lymphoma\/leukemia","volume":"95","author":"Burkhardt","year":"2016","journal-title":"Ann Hematol"},{"key":"B141","first-page":"1454","article-title":"Fc\u03b3RIIa-H131R variant is associated with inferior response in diffuse large B cell lymphoma: a meta-analysis of genetic risk","volume":"21","author":"Ziakas","year":"2016","journal-title":"J BUON"},{"key":"B142","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1074\/mcp.M117.066944","article-title":"Identification of Fc gamma receptor glycoforms that produce differential binding kinetics for rituximab","volume":"16","author":"Hayes","year":"2017","journal-title":"Mol Cell Proteomics"},{"key":"B143","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/1756-8722-5-51","article-title":"Homozygous A polymorphism of the complement C1qA276 correlates with prolonged overall survival in patients with diffuse large B cell lymphoma treated with R-CHOP","volume":"5","author":"Jin","year":"2012","journal-title":"J Hematol Oncol"},{"key":"B144","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1158\/1078-0432.CCR-16-1275","article-title":"Complement-regulatory proteins CFHR1 and CFHR3 and patient response to anti-CD20 monoclonal antibody therapy","volume":"23","author":"Rogers","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B145","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1080\/17474086.2017.1356714","article-title":"Is now the time for molecular driven therapy for diffuse large B-cell lymphoma?","volume":"10","author":"Di Rocco","year":"2017","journal-title":"Expert Rev Hematol"},{"key":"B146","doi-asserted-by":"publisher","first-page":"293","DOI":"10.3322\/caac.21197","article-title":"Predictive biomarkers may help individualize treatment for patients with follicular lymphoma","volume":"63","author":"Barton","year":"2013","journal-title":"CA Cancer J Clin"},{"key":"B147","doi-asserted-by":"publisher","first-page":"a001719","DOI":"10.1101\/mcs.a001719","article-title":"Diffuse large B-cell lymphoma: can genomics improve treatment options for a curable cancer?","volume":"3","author":"Amin","year":"2017","journal-title":"Cold Spring Harb Mol Case Stud"},{"key":"B148","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1002\/ijc.30838","article-title":"TP53 mutation and survival in aggressive B cell lymphoma","volume":"141","author":"Zenz","year":"2017","journal-title":"Int J Cancer"},{"key":"B149","doi-asserted-by":"publisher","first-page":"3986","DOI":"10.1182\/blood-2012-05-433334","article-title":"Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study","volume":"120","author":"Xu-Monette","year":"2012","journal-title":"Blood"},{"key":"B150","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1038\/leu.2011.378","article-title":"BCL2 mutations in diffuse large B-cell lymphoma","volume":"26","author":"Schuetz","year":"2012","journal-title":"Leukemia"},{"key":"B151","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.exphem.2006.02.015","article-title":"The anti-lymphoma effect of antibody-mediated immunotherapy is based on an increased degranulation of peripheral blood natural killer (NK) cells","volume":"34","author":"Fischer","year":"2006","journal-title":"Exp Hematol"},{"key":"B152","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/sj.bjc.6602930","article-title":"Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?","volume":"94","author":"Arnould","year":"2006","journal-title":"Br J Cancer"},{"key":"B153","doi-asserted-by":"publisher","first-page":"3773","DOI":"10.1182\/blood-2008-09-177469","article-title":"Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival","volume":"113","author":"Johnson","year":"2009","journal-title":"Blood"},{"key":"B154","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1093\/annonc\/mdm345","article-title":"The challenge of biosimilars","volume":"19","author":"Mellstedt","year":"2008","journal-title":"Ann Oncol"},{"key":"B155","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2147\/BS.S20681","article-title":"Rituximab and biosimilars \u2013 equivalence and reciprocity","volume":"2013","author":"Qureshi","year":"2013","journal-title":"Biosimilars"},{"key":"B156","doi-asserted-by":"publisher","first-page":"2696","DOI":"10.1002\/bit.26438","article-title":"Biosimilars: key regulatory considerations and similarity assessment tools","volume":"114","author":"Kirchhoff","year":"2017","journal-title":"Biotechnol Bioeng"},{"key":"B157","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1002\/btpr.2066","article-title":"Biosimilars advancements: moving on to the future","volume":"31","author":"Tsuruta","year":"2015","journal-title":"Biotechnol Prog"},{"key":"B158","doi-asserted-by":"publisher","first-page":"466","DOI":"10.4161\/mabs.2.5.12720","article-title":"Cell culture processes for monoclonal antibody production","volume":"2","author":"Li","year":"2010","journal-title":"MAbs"},{"key":"B159","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1080\/17512433.2017.1359537","article-title":"Pharmacokinetics, efficacy and safety of the rituximab biosimilar CT-P10","volume":"10","author":"Coiffier","year":"2017","journal-title":"Expert Rev Clin Pharmacol"},{"key":"B160","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.trac.2013.02.014","article-title":"Analytical characterization of biosimilar antibodies and Fc-fusion proteins","volume":"48","author":"Beck","year":"2013","journal-title":"TrAC Trends Anal Chem"},{"key":"B161","doi-asserted-by":"publisher","first-page":"15073","DOI":"10.1074\/jbc.M701654200","article-title":"Structural basis for recognition of CD20 by therapeutic antibody rituximab","volume":"282","author":"Du","year":"2007","journal-title":"J Biol Chem"},{"key":"B162","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.jpba.2017.03.029","article-title":"Comparability study of rituximab originator and follow-on biopharmaceutical","volume":"140","author":"Montacir","year":"2017","journal-title":"J Pharm Biomed Anal"},{"key":"B163","doi-asserted-by":"publisher","first-page":"3823","DOI":"10.1016\/j.molimm.2007.06.151","article-title":"Mechanisms of killing by anti-CD20 monoclonal antibodies","volume":"44","author":"Glennie","year":"2007","journal-title":"Mol Immunol"},{"key":"B164","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1053\/j.seminhematol.2010.02.003","article-title":"Rituximab: therapeutic benefit! Vitamin R?","volume":"47","author":"Mo","year":"2010","journal-title":"Semin Hematol"},{"key":"B165","doi-asserted-by":"publisher","first-page":"7359","DOI":"10.1038\/sj.onc.1206939","article-title":"Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance","volume":"22","author":"Smith","year":"2003","journal-title":"Oncogene"},{"key":"B166","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/j.semarthrit.2015.04.002","article-title":"Clinical trial development for biosimilars","volume":"44","author":"Alten","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"B167","unstructured":"Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference Product2016"},{"key":"B168","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1038\/nbt.2760","article-title":"The INN crowd","volume":"31","year":"2013","journal-title":"Nat Biotechnol"},{"key":"B169","doi-asserted-by":"publisher","first-page":"339","DOI":"10.4103\/0253-7613.157140","article-title":"Biosimilars: the naming puzzle","volume":"47","author":"Gaur","year":"2015","journal-title":"Indian J Pharmacol"},{"key":"B170","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.jacbts.2016.03.002","article-title":"Drugs, devices, and the FDA: part 1: an overview of approval processes for drugs","volume":"1","author":"Van Norman","year":"2016","journal-title":"JACC Basic Transl Sci"},{"key":"B171","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1097\/MLR.0000000000000486","article-title":"Estimating the population benefits and costs of rituximab therapy in the United States from 1998 to 2013 using real-world data","volume":"54","author":"Danese","year":"2016","journal-title":"Med Care"},{"key":"B172","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/nrd.2017.113","article-title":"Market watch: strategies for biosimilars in emerging markets","volume":"16","author":"Gautam","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"B173","unstructured":"CJSC BIOCAD Announces AcellBia Is First mAb Biosimilar Approved by the Ministry of Health of the Russian Federation2014"},{"key":"B174","unstructured":"Safety and Efficacy Study of BCD-020 in Therapy of Indolent Non-Hodgkin\u2019s Lymphoma2012"},{"key":"B175","unstructured":"The Medicine Maker2017"},{"key":"B176","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s40259-017-0232-7","article-title":"Efficacy, safety and pharmacokinetics of up to two courses of the rituximab biosimilar CT-P10 versus innovator rituximab in patients with rheumatoid arthritis: results up to week 72 of a phase I randomized controlled trial","volume":"31","author":"Yoo","year":"2017","journal-title":"BioDrugs"},{"key":"B177","doi-asserted-by":"publisher","first-page":"e362","DOI":"10.1016\/S2352-3026(17)30120-5","article-title":"Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial","volume":"4","author":"Kim","year":"2017","journal-title":"Lancet Haematol"},{"key":"B178","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1136\/annrheumdis-2017-211281","article-title":"A randomised, double-blind trial to demonstrate bioequivalence of GP2013 and reference rituximab combined with methotrexate in patients with active rheumatoid arthritis","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B179","doi-asserted-by":"publisher","first-page":"e350","DOI":"10.1016\/S2352-3026(17)30106-0","article-title":"Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma (ASSIST-FL): primary results from a confirmatory phase 3, double-blind, randomised, controlled study","volume":"4","author":"Jurczak","year":"2017","journal-title":"Lancet Haematol"},{"key":"B180","unstructured":"A Study to Evaluate Safety, Tolerability, PK and PD of HLX01 in Patients with CD20-Positive B-Cell Lymphomas2017"},{"key":"B181","unstructured":"A Pharmacokinetic and Pharmacodynamic Study Comparing HLX01 and Rituximab in Patients with CD20-Positive, B-Cell Lymphoma2015"},{"key":"B182","unstructured":"Clinical Study to Compare the Efficacy and Safety of Rituximab Biosimilar HLX01 and Rituximab in Combination with CHOP, in Previously Untreated Subjects with CD20+ DLBCL2016"},{"key":"B183","unstructured":"A Randomised, Double-Blind, Phase I\/II Study to Evaluate the PK, PD, Safety, and Efficacy Between HLX01 and Rituximab in Patients with Moderate to Severe Rheumatoid Arthritis and Inadequate Response to Treatment with DMARDs2017"},{"key":"B184","unstructured":"Biosimilars in low- and middle-income markets: a case study of India and RussiaASCO Annual Meeting2016"},{"key":"B185","unstructured":"Guidelines On Evaluation Of Similar Biotherapeutic Products (SBPs)2009"},{"key":"B186","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.drudis.2011.08.001","article-title":"The regulatory framework of biosimilars in the European Union","volume":"17","author":"Minghetti","year":"2012","journal-title":"Drug Discov Today"},{"key":"B187","doi-asserted-by":"publisher","first-page":"292","DOI":"10.4103\/0971-5851.125248","article-title":"Comparison of the efficacy and safety of rituximab (MabtheraTM) and its biosimilar (RedituxTM) in diffuse large B-cell lymphoma patients treated with chemo-immunotherapy: a retrospective analysis","volume":"34","author":"Roy","year":"2013","journal-title":"Indian J Med Paediatr Oncol"},{"key":"B188","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s00280-016-3083-x","article-title":"Population pharmacokinetics of RedituxTM, a biosimilar rituximab, in diffuse large B-cell lymphoma","volume":"78","author":"Gota","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"B189","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1007\/s00280-016-3176-6","article-title":"Gota et al. on their article \u2019the pharmacokinetics of RedituxTM, a biosimilar of rituximab\u2019","volume":"78","author":"Tout","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"B190","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.4049\/jimmunol.1202588","article-title":"Comparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties","volume":"190","author":"Rafiq","year":"2013","journal-title":"J Immunol"},{"key":"B191","doi-asserted-by":"publisher","first-page":"436","DOI":"10.2146\/ajhp120035","article-title":"Stability of stock and diluted rituximab","volume":"70","author":"Zhang","year":"2013","journal-title":"Am J Health Syst Pharm"},{"key":"B192","volume-title":"1B8 vs MabThera","year":"2018"},{"key":"B193","unstructured":"ICTRP Search Portal2016"},{"key":"B194","unstructured":"Study to Assess if ABP798 Is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab2016"},{"key":"B195","unstructured":"A Multicenter Open-Label Randomized Study of BCD-020 (Rituximab, CJSC BIOCAD, Russia) Efficacy and Safety in Comparison with MabThera (F. Hoffmann-La Roche Ltd., Switzerland) in Monotherapy of CD20-Positive Indolent Non-Hodgkin\u2019s Lymphoma \u2013 AdisInsight2017"},{"key":"B196","unstructured":"China accepts JHL\u2019s bid to conduct trials2017"},{"key":"B197","unstructured":"Safety and Efficacy Study of BCD-020 in Therapy of Indolent Non-Hodgkin\u2019s Lymphoma2012"},{"key":"B198","unstructured":"Biosimilars in low- and middle-income markets: a case study of India and RussiaASCO Annual Meeting2016"},{"key":"B199","unstructured":"BI 695500 vs Rituxan First Line Treatment in Patients with Low Tumor Burden Follicular Lymphoma2015"},{"key":"B200","unstructured":"Guidelines in Practice"},{"key":"B201","unstructured":"GP2013 in the Treatment of Patients with Previously Untreated, Advanced Stage Follicular Lymphoma2011"},{"key":"B202","unstructured":"A Phase III Study of JHL1101 (Rituximab Biosimilar) in Patients with Non-Hodgkin\u2019s Lymphoma \u2013 AdisInsight2017"},{"key":"B203","unstructured":""},{"key":"B204","volume-title":"Similar Biotherapeutic Products Approved and Marketed in Latin America\/General\/Biosimilars\/Home","year":"2013"},{"key":"B205","doi-asserted-by":"publisher","first-page":"910763","DOI":"10.1155\/2015\/910763","article-title":"Assessment of physicochemical properties of rituximab related to its immunomodulatory activity","volume":"2015","author":"Miranda-Hern\u00e1ndez","year":"2015","journal-title":"J Immunol Res"},{"key":"B206","unstructured":"Maball 500mg Injection: Uses, Price, Side Effects, Composition, Substitutes, Precautions and Advice \u2013 Hetero Drugs Ltd Vial of 50 ml Injection. 1mg2018"},{"key":"B207","unstructured":"ShubhadeepS A Randomized, Multiple-Dose, Multicenter, Comparative Parallel Study to Evaluate the Pharmacokinetic Characteristics of Intravenous Infusion of Rituximab (Hetero) and Reference Medicinal Product (Rituximab, Roche) in Indian Patients of NonHodgkin\u2019s Lymphoma2017"},{"key":"B208","unstructured":"MabionCD202015"},{"key":"B209","unstructured":"MabtasRA 500mg Injection: Uses, Price, Side Effects, Composition, Substitutes, Precautions and Advice \u2013 Intas Pharmaceuticals Ltd Vial of 50 ml Injection 1mg2018"},{"key":"B210","volume-title":"\u2018Similar Biologics\u2019 Approved and Marketed in India\/General\/Biosimilars\/Home","year":"2012"},{"key":"B211","unstructured":"A Prospective, Multi Centre, Observational, Data Collection Registry Study To Monitor The Routine Clinical Use Of Mabtas (Rituximab 100 Mg\/500 Mg Concentrate For Solution For Infusion, Manufactured By Intas Pharmaceuticals Ltd) In Indian Patients \u2013 Mabtas Registry \u2013 AdisInsight2016"},{"key":"B212","unstructured":"Clinical Trials Register \u2013 Search for MK-88082013"},{"key":"B213","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.1182\/blood.V128.22.3568.3568","article-title":"Pharmacovigilance of a rituximab biosimilar (Novex) in Argentina","volume":"128","author":"Milone","year":"2016","journal-title":"Blood"},{"key":"B214","unstructured":"Precios de \u2018NOVEX\u2019 (Lab. ELEA) \u2013 Kairos Web Argentina"},{"key":"B215","unstructured":"A Study of PF-05280586 (Rituximab-Pfizer) or MabThera2018"},{"key":"B216","unstructured":"Reditux Injection-Manufacturers & Suppliers in India"},{"key":"B217","doi-asserted-by":"publisher","first-page":"17","DOI":"10.4103\/ASJO.ASJO_29_16","article-title":"A phase III, multicentric, open-label, two-arm, parallel group, active-control, randomized, comparative clinical study to evaluate efficacy and safety of RituxiRel\u2122 arm (rituximab) with reference arm (rituximab) in patients with non-Hodgkin\u2019s lymphoma","volume":"3","author":"Apsangikar","year":"2017","journal-title":"Asian J Oncol"},{"key":"B218","unstructured":"Rituxirel 500mg Injection: Uses, Price, Side Effects, Composition, Substitutes, Precautions and Advice \u2013 Reliance Life Sciences vial of 50 ml Injection. 1mg"},{"key":"B219","unstructured":"Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients with Non Hodgkin\u2019s Lymphoma2017"},{"key":"B220","unstructured":"A Randomized, Double-Blind, Multi-Center, Multi-National Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-Line Immunotherapy Treatment in Patients with Low Tumor Burden Follicular Lymphoma2018"},{"key":"B221","volume-title":"Teva Halts Phase III Biosimilar Rituximab Trial\/News\/Biosimilars\/Home","year":"2012"},{"key":"B222","doi-asserted-by":"publisher","first-page":"26","DOI":"10.5639\/gabij.2013.0201.008","article-title":"Current status of biopharmaceuticals in Iran\u2019s pharmaceutical market","volume":"2","author":"Majid Cheraghali","year":"2013","journal-title":"Generics Biosimilars Initiat J"},{"key":"B223","unstructured":"Ristova 500 mg Injection. Rituximab 500mg Price. Buy Ristova 500 mg"},{"key":"B224","unstructured":"BIOCAD\u2019s-Rituximab-Biosimilar-to-Receive-MA-Soon-in-India2017"},{"key":"B225","unstructured":"Truxima2017"},{"key":"B226","volume-title":"Truxima Receives Approval in EU for Autoimmune, Oncology Indications","year":"2017"},{"key":"B227","unstructured":"2018"},{"key":"B228","first-page":"1794","article-title":"Biosimilars in Two Developing Economies of South America (Argentina and Brazil) and One Developed Economy of Oceania (Australia). Facts, Regulations and Evolution","volume":"7","author":"Bas","year":"2016","journal-title":"Res J Pharm Biol Chem Sci"},{"key":"B229","unstructured":"Biosimilars Applications Approved & Under Review2015"},{"key":"B230","unstructured":"Developing Biosimilars"},{"key":"B231","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.biologicals.2011.06.024","article-title":"Clinical programs in the development of similar biotherapeutic products: rationale and general principles","volume":"39","year":"2011","journal-title":"Biologicals"},{"key":"B232","unstructured":"UPDATE 2-spectrum pharma to make biosimilar of Roche\u2019s rituximabReuters2011"},{"key":"B233","unstructured":"Monoclonal Antibodies (mAbs) Market Size Worth $138.6 Billion by 20242016"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2018.00163\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T02:14:42Z","timestamp":1604369682000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2018.00163\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,4]]},"references-count":233,"alternative-id":["10.3389\/fonc.2018.00163"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2018.00163","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,4]]},"article-number":"163"}}